Alternative complement pathway
The alternative pathway is one of three complement pathways that opsonize and kill pathogens. The pathway is triggered when the C3b protein directly binds the microbe.
Bb remains part of the C3(H2O) to form C3(H2O)Bb. This complex is also known as a fluid-phase C3-convertase. This convertase, although only produced in small amounts, can cleave multiple C3 proteins into C3a and C3b.
The alternative pathway C3-convertase consists of the activated B and C3b factors, forming an unstable compound that can become stable after binding properdin, a serum protein.
After the creation of C3 convertase, the complement system follows the same path regardless of the means of activation (alternative, classical, or lectin). Binding of another C3b-fragment to the C3-convertase of the alternative pathway creates a C5-convertase analoguous to the lectin or classical pathway.
The C5-convertase of the alternative pathway consists of C3bBbC3b also referred to as C3b2Bb (instead of C4b2a3b in the other pathways).
Since C3b is free and abundant in the plasma, it can bind to either a host cell or a pathogen surface. To prevent complement activation from proceeding on the host cell, there are several different kinds of regulatory proteins that disrupt the complement activation process:
- Complement Receptor 1 (CR1 or CD35) and DAF (decay accelerating factor also known as CD55) compete with Factor B in binding with C3b on the cell surface and can even remove Bb from an already formed C3bBb complex
- The formation of a C3 convertase can also be prevented when a plasma protease called complement factor I cleaves C3b into its inactive form, iC3b. Factor I requires a C3b-binding protein cofactor such as complement factor H, CR1, or Membrane Cofactor of Proteolysis (MCP or CD46)
- Complement Factor H can inhibit the formation of the C3 convertase by competing with factor B for binding to C3b; accelerate the decay of the C3 convertase; and act as a cofactor for Factor I-mediated cleavage of C3b. Complement factor H preferentially binds to vertebrate cells (because of affinity for sialic acid residues), allowing preferential protection of host (as opposed to bacterial) cells from complement-mediated damage.
- CFHR5 (Complement Factor H-Related protein 5) is able to bind to act as a cofactor for factor I, has decay accelerating activity and is able to bind preferentially to C3b at host surfaces.
- Conrad DH, Carlo JR, Ruddy S (June 1978). "Interaction of beta1H globulin with cell-bound C3b: quantitative analysis of binding and influence of alternative pathway components on binding". J. Exp. Med. 147 (6): 1792–1805. doi:10.1084/jem.147.6.1792. PMC 2184316. PMID 567241.
- Weiler JM, Daha MR, Austen KF, Fearon DT (September 1976). "Control of the amplification convertase of complement by the plasma protein beta1H". Proc. Natl. Acad. Sci. U.S.A. 73 (9): 3268–72. doi:10.1073/pnas.73.9.3268. PMC 431003. PMID 1067618.
- Pangburn MK, Schreiber RD, Müller-Eberhard HJ (July 1977). "Human complement C3b inactivator: isolation, characterization, and demonstration of an absolute requirement for the serum protein beta1H for cleavage of C3b and C4b in solution". J. Exp. Med. 146 (1): 257–70. doi:10.1084/jem.146.1.257. PMC 2180748. PMID 301546.
- McRae JL, Duthy TG, Griggs KM, et al. (May 2005). "Human factor H-related protein 5 has cofactor activity, inhibits C3 convertase activity, binds heparin and C-reactive protein, and associates with lipoprotein". J. Immunol. 174 (10): 6250–6. PMID 15879123.
- Immunobiology. Janeway, et al. 5th 3ed. ISBN 0-8153-4101-6. (5th ed. text online at .)
- BioCarta's diagram of the alternative pathway,